Can damaged sensory neurons and gabapentin’s calcium-channel binding help explain post-herpetic neuralgia pain?

Post-herpetic neuralgia (PHN) arises after varicella-zoster reactivation injures sensory pathways, and gabapentin has established clinical analgesic benefit in this setting. The claim is directionally consistent with current neurobiology, but both the ectopic-firing and neurotransmitter-release portions are mechanistically plausible rather than definitive.

PHN pain mechanisms

• Varicella-zoster–related inflammation and injury of dorsal-root-ganglion neurons and peripheral afferents, including neuronal loss, are established features of PHN.
• Peripheral sensitization can lower nociceptor thresholds and increase responsiveness, contributing to spontaneous pain, hyperalgesia, and allodynia.
• Injured axons, nerve endings, and dorsal-root-ganglion somata may act as hyperexcitable ectopic pacemakers, generating impulses without external stimulation. This offers a credible explanation for ongoing pain and possibly for maintaining central sensitization.
• However, spontaneous ectopic firing specifically attributable to VZV injury has not been directly demonstrated electrophysiologically in people with established PHN. Deafferentation and central sensitization also contribute, with relative importance varying between patients.

Gabapentin mechanism and effectiveness

• Gabapentin binding to voltage-gated calcium-channel auxiliary α2δ-1 and α2δ-2 subunits—preferentially α2δ-1—is firmly established.
• Randomized PHN trials found significantly greater pain-score reductions and higher proportions achieving at least 50% pain reduction with gabapentin than placebo.
• Rather than simply acutely blocking calcium-channel current, gabapentin can disrupt calcium-channel trafficking to the cell surface. This provides a coherent route to reduced presynaptic excitatory signaling, including glutamate release.
• Reduced excitatory transmitter release has been observed in pain-model preparations, but is context- and time-dependent, not a universal immediate consequence of gabapentin exposure.

Bottom line

• The claim accurately identifies sensory-neuron injury and gabapentin’s α2δ target. Ectopic discharges and reduced excitatory neurotransmitter release are credible contributing mechanisms, but should be described as plausible, heterogeneous pathways rather than proven universal explanations for PHN pain or gabapentin analgesia.